Pentetreotide 

Pentetreotide is a diethylenetriaminopentaacetic (DTPA) conjugate of Octreotide (HY-P0036). Pentetreotide is an indium-labelled somatostatin analog and can be uesd to nuclear medicine imaging. Somatostatin receptor scintigraphy with Pentetreotide is effective in visualizing neuroendocrine tumors, and its metastasis^[1][2].

Neuroendocrine tumors have an increased number of somatostatin receptors, as compared to normal tissues. At present time, there are five known subtypes. Somatostatin receptor scintigraphy with ¹¹¹In-Pentetreotide binds to two of these subtypes and is effective in visualizing neuroendocrine tumors, and its metastasis with an overall diagnostic sensitivity of 70% to 90%. It is considerably more sensitive than conventional anatomic imaging. Its usage in neuroendocrine tumors not only includes assessment of disease extent, but also in identified primary lesion, assesses treatment response, and selection for radionuclide therapy^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1394.57

C₆₃H₈₇N₁₃O₁₉S₂

138661-02-6

Gly-{D-Phe}-Cys-Phe-{D-Trp}-Lys-Thr-Cys-Thr (Disulfide bridge: Cys3-Cys8)

G{D-Phe}CF{D-Trp}KTCT (Disulfide bridge: Cys3-Cys8)

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Al-Suqri B. 111 In-pentetreotide SPECT CT Value in Follow-up of Patients with Neuro-Endocrine Tumors. Oman Med J. 2014 Sep;29(5):362-4.  [Content Brief]

  [2]. Masuda R, et al. Concise site-specific synthesis of DTPA-peptide conjugates: application to imaging probes for the chemokine receptor CXCR4. Bioorg Med Chem. 2011 May 15;19(10):3216-20.  [Content Brief]